KURA•Kura Oncology and Kyowa Kirin will present initial results from ziftomenib-FLT3 inhibitor combination trials at ASH on Dec. 12-15, 2026, in New Orleans.
The trials evaluate ziftomenib with quizartinib in newly diagnosed AML and with gilteritinib in relapsed or refractory disease, targeting patients with NPM1 and FLT3 co-mutations. Kura Oncology will also present longer-term frontline results with venetoclax and azacitidine supporting the ongoing Phase 3 KOMET-017 registrational trial, along with an exploratory analysis of activity in additional molecularly defined patient groups.
